Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease, A meta-regression analysis

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 892-897

  Fadini, Gian Paolo ^a,b   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Bone marrow; Cell therapy; Regeneration

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CARDIOVASCULAR DISEASE; CD34 SELECTION; CELL COUNT; CORRELATION ANALYSIS; DATA EXTRACTION; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; REGRESSION ANALYSIS; RISK FACTOR; STEM CELL MOBILIZATION; TREATMENT FAILURE;

BONE MARROW; CELL THERAPY; REGENERATION;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; REGRESSION ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84885302743     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.089     Document Type: Article

References (48)

1. Fadini GP, Avogaro A. It is all in the blood: the multifaceted contribution of circulating progenitor cells in diabetic complications. Exp Diabetes Res 2012;2012: 742976.
2. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 2012;110:624-37.
3. Takahashi T, Kalka C, Masuda H, et al. Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-8.
4. Yeh ET, Zhang S, Wu HD, et al. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 2003;108:2070-3.
5. Chavakis E, Koyanagi M, Dimmeler S. Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back. Circulation 2010;121: 325-35.
6. Zohlnhofer D, Dibra A, Koppara T, et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J Am Coll Cardiol 2008;51:1429-37.
7. Fadini GP, Boscaro E, de Kreutzenberg S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010;33:1097-102.
8. Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol 2006;26:257-66.
9. Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006;49:3075-84.
10. Busik JV, TikhonenkoM, Bhatwadekar A, et al. Diabetic retinopathy is associatedwith bone marrow neuropathy and a depressed peripheral clock. J Exp Med 2009;206: 2897-906.
11. Oikawa A, Siragusa M, Quaini F, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol 2010;30:498-508.
12. Orlandi A, Chavakis E, Seeger F, et al. Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice. Basic Res Cardiol 2010;105:703-12.
13. Ferraro F, Lymperi S, Mendez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011;3 [104ra101].
14. Higgins JPT, Green S; Editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. The Cochrane Library Issue 4 Chichester. UK: JohnWiley & Sons, Ltd; 2006.
15. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73
16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
17. Burt RK, Testori A, Oyama Y, et al. Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia. Bone Marrow Transplant 2010;45:111-6.
18. Onodera R, Teramukai S, Tanaka S, et al. Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis. Bone Marrow Transplant 2011;46: 278-84.
19. Jeevanantham V, Butler M, Saad A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation 2012;126:551-68.
20. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012;2 [CD006536].
21. DiPersio JF. Diabetic stem-cell "mobilopathy". N Engl J Med 2011;365:2536-8.
22. Fadini GP,Maruyama S, Ozaki T, et al. Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One 2010;5:e11488.
23. Leone AM, Rutella S, Bonanno G, et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J 2005;26: 1196-204.
24. Leone AM, Rutella S, Bonanno G, et al. Endogenous G-CSF and CD34+cell mobilization after acute myocardial infarction. Int J Cardiol 2006;111:202-8.
25. Fadini GP. Is bone marrow another target of diabetic complications? Eur J Clin Invest 2011;41:457-63.
26. Achilli F,Malafronte C, Lenatti L, et al. Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the singleblind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur J Heart Fail 2010;12:1111-21.
27. Arai M, Misao Y, Nagai H, et al. Granulocyte colony-stimulating factor: a noninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J 2006;70:1093-8.
28. Boyle AJ, Whitbourn R, Schlicht S, et al. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol 2006;109:21-7.
29. Chih S, Macdonald PS, McCrohon JA, et al. Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trial. Heart 2012;98:282-90.
30. Ellis SG, Penn MS, Bolwell B, et al. Granulocyte colony stimulating factor in patients with large acute myocardial infarction: results of a pilot dose-escalation randomized trial. Am Heart J 2006;152:1051 [e1059-1014].
31. Engelmann MG, Theiss HD, Hennig-Theiss C, et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006;48:1712-21.
32. Huttmann A, Duhrsen U, Stypmann J, et al. Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure-feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol 2006;101:78-86.
33. Ince H, Petzsch M, Kleine HD, et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 2005;112:I73-80.
34. Ince H, PetzschM, Kleine HD, et al. Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acutemyocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI). Circulation 2005;112:3097-106.
35. Karimabad HM, Shabestari M, Baharvand H, et al. Lack of beneficial effects of granulocyte colony-stimulating factor in patients with subacute myocardial infarction undergoing late revascularization: a double-blind, randomized, placebo-controlled clinical trial. Acta Cardiol 2011;66:219-24.
36. Kuethe F, Figulla HR, Herzau M, et al. Treatment with granulocyte colonystimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 2005;150:115.
37. Kovacic JC, Macdonald P, Feneley MP, et al. Safety and efficacy of consecutive cycles of granulocyte-colony stimulating factor, and an intracoronary CD133+ cell infusion in patients with chronic refractory ischemic heart disease: the G-CSF in angina patients with IHD to stimulate neovascularization (GAIN I) trial. Am Heart J 2008;156:954-63.
38. Leone AM, Galiuto L, Garramone B, et al.Usefulness of granulocyte colony-stimulating factor in patientswith a large anteriorwall acutemyocardial infarction to prevent left ventricular remodeling (the rigenera study). Am J Cardiol 2007;100:397-403.
39. Losordo DW, Schatz RA, White CJ, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa doubleblind, randomized controlled trial. Circulation 2007;115:3165-72.
40. Ripa RS, Haack-Sorensen M, Wang Y, et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 2007;116:I24-30.
41. Ripa RS,Wang Y, Jorgensen E, et al. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006;27:1785-92.
42. Sprigg N, Bath PM, Zhao L, et al. Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the Stem cell Trial of recovery EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). Stroke 2006;37:2979-83.
43. Stein A, Zohlnhofer D, Pogatsa-Murray G, et al. Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. Thromb Haemost 2010;103:638-43.
44. Suzuki K, Nagashima K, Arai M, et al. Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Circ J 2006;70:430-7.
45. Takano H, Hasegawa H, Kuwabara Y, et al. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int J Cardiol 2007;122:41-7.
46. Valgimigli M, Rigolin GM, Cittanti C, et al. Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005;26: 1838-45.
47. Wang S, Cui J, Peng W, Lu M. Intracoronary autologous CD34+ stem cell therapy for intractable angina. Cardiology 2010;117:140-7.
48. Wolfram O, Jentsch-Ullrich K, Wagner A, et al. G-CSF-induced mobilization of CD34(+) progenitor cells and proarrhythmic effects in patients with severe coronary artery disease. Pacing Clin Electrophysiol 2007;30(Suppl. 1):S166-9.